In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 6, 2007, Pages 1391-1394

  Laue, H ^a   Weiss, L ^a   Bernardi, A ^a,b   Hawser, S ^a   Lociuro, S ^a   Islam, K ^a  

^a Arpida Ltd   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibiotic; Chequerboard; Staphylococcus aureus; Synergy

Indexed keywords

AMINOGLYCOSIDE; AMINOPYRIDINE DERIVATIVE; AMPICILLIN; ANTIINFECTIVE AGENT; AZTREONAM; BACITRACIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFSULODIN; CLOXACILLIN; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID; GENTAMICIN; ICLAPRIM; LATAMOXEF; LINCOSAMIDE; MACROLIDE; METRONIDAZOLE; OXACILLIN; PENICILLIN G; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; PUROMYCIN; QUINOLONE DERIVATIVE; SULFADIAZINE; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; UNINDEXED DRUG;

ANAEROBIC BACTERIUM; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; NONHUMAN;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; FOLIC ACID ANTAGONISTS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES;

EID: 36448992626     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm409     Document Type: Article

References (10)

1. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 2006; 71: 941-8.
2. Schneider P, Hawser S, Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 2003; 13: 4217-21.
3. Kohlhoff SA, Roblin PM, Rezn1k T et al. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob Agents Chernother 2004; 48: 1885-6.
4. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
5. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2007.
6. Eliopoulos GM, Moellering RC, Jr. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. Baltimore: The Williams & Wilkins Co, 1991; 432-92.
7. Bushby SRM. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol 1968; 33: 72-90.
8. Locher HH, Schlunegger H, Hartman PG et al. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother 1996; 40: 1376-81.
9. Wust J, Schwarzenbach J. Activity of brodimoprim and metioprim alone and in combination with sulfonamides against anaerobic bacteria. Antimicrob Agents Chemother 1983; 23: 490-2.
10. Then RL. Diaminopyrimidines. In: Finch RG, Greenwood D, Ragnar Norrby S et al., eds, Antibiotics and Chemotherapy. Anti-infective Agents and Their Use in Therapy. Oxford: Churchill Livingstone, 2003; 284-93.